A method for treating a metabolic disorder associated with abnormal bodyweight in a subject is provided, the method including administering to the subject an effective amount of a compound that modulates phosphatidylinositol 5-phosphate 4-kinase beta (PI5P4Kβ) activity, wherein a PI5P4Kβ inhibitor is administered when the subject suffers from a metabolic disorder associated with an underweight bodyweight; and wherein a PI5P4Kβ agonist is administered when the subject suffers from a metabolic disorder associated with an overweight or obese bodyweight. Also provided herein are methods of increasing meat quality and/or yield in livestock or domesticated poultry by administering to an animal an effective amount of a PI5P4Kβ inhibitor, and genetically engineered animals having a substitution in PI5P4Kβ that reduces its GTP-sensing activity.

The present disclosure generally relates to compositions and methods of use thereof for treating heart failure encompassing administering a composition of modified mRNA (modRNA) encoding for type 2 phosphatidylinositol-5-phosphate 4-kinase gamma (pip4k2c) to heart tissue of a subject in need thereof.

As described herein, phosphatidylinositol-5-phosphate 4-kinases (PIP4Ks) have an allosteric function in addition to their catalytic activity. The allosteric function suppresses PIP5K-mediated PI(4,5)P.sub.2 synthesis and insulin-dependent conversion to PI(3,4,5)P.sub.3. Further described herein are methods for treatment of diabetes, metabolic syndrome, insulin resistance, a obesity, cancer, immune deficiency, autoimmune disease, infection, or a combination thereof.

Described herein are compositions and methods for inhibiting, degrading, knocking down or knocking out pip4k2c nucleic acids or Pip4k2c protein. Such compositions and methods are useful for treating and inhibiting the onset of cancer.